Physician profile
Peter C Serpico
NPI 1306892401
$13,351.97
in general payments reported to CMS, 2019-2025
39 companies · $2,957 in 2025
The $2,957 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,144 · 2020: $1,582 · 2021: $765 · 2022: $1,406 · 2023: $2,365 · 2024: $2,133 · 2025: $2,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,454.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,651.70 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,653.55 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $777.54 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $632.17 | 2019-2025 | |
| Genentech USA, INC. | $604.09 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $556.07 | 2019-2025 | Dupixent |
| Insmed, INC. | $541.42 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $413.66 | 2020-2025 | Wakix |
| Mylan Specialty L.P. | $389.28 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $359.76 | 2019-2025 | |
| Philips North America LLC | $260.78 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $232.66 | 2019-2024 | |
| Axsome Therapeutics, INC. | $218.16 | 2023-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $207.55 | 2019-2023 | Uptravi, Opsumit |
| Verona Pharma, INC. | $195.53 | 2025 | Ohtuvayre |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $194.07 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $186.87 | 2020-2025 | Aralast |
| Electromed, INC. | $146.26 | 2023-2025 | Smartvest |
| Resmed Corp | $105.47 | 2019-2025 | |
| Vifor Pharma, INC. | $104.63 | 2024-2025 | Zemaira |
| Grifols USA, LLC | $96.59 | 2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $96.03 | 2024-2025 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $90.24 | 2023-2025 | Lumryz |
| Sunovion Pharmaceuticals INC. | $67.83 | 2019-2020 | |
| Lilly USA, LLC | $67.71 | 2025 | Zepbound, Mounjaro |
| Inspire Medical Systems, INC. | $65.21 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $64.81 | 2019-2025 | |
| United Therapeutics Corporation | $57.47 | 2024-2025 | Tyvaso, Tyvaso |
| Pulmonx Corporation | $57.28 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Ani Pharmaceuticals, INC. | $54.63 | 2023-2025 | Purified Cortrophin Gel |
| Circassia INC. | $41.66 | 2019 | |
| Inogen, INC. | $34.38 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Teva Pharmaceuticals USA, INC. | $25.86 | 2019-2021 | |
| Baxter Healthcare | $25.02 | 2024 | Hillrom - Life 2000 Ventilation System |
| Kaleo, INC. | $17.38 | 2021 | |
| Shire North American Group INC | $16.99 | 2019 | |
| Viatris Specialty LLC | $15.47 | 2025 | Yupelri |
| Advanced Respiratory, INC | $13.15 | 2019 | |
| Eisai INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Serpico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.